Shots:

• The US FDA has granted FT Designation to LX1001 for the treatment of APOE4 associated AD. The designation evaluates to facilitate the development and expedite the review of drug
• The company has initiated P-I trial to assess the safety and toxicity of LX1001 as a potential one-time treatment for early-stage AD patients with mild cognitive impairment who are APOE4 homozygous
• The study will establish a maximum tolerable dose and is expected to complete dosing of 15 patients in 2021 while the initial P-I clinical data are expected in the H2’21

  Ref: Globe Newswire | Image: Yahoo Finance